App Economy Insights
$SPOT Spotify just hit 751M users. 🎧

Let's review the story.

• New co-CEOs
• Margin expansion
• Ad revenue vs. Big Tech
• Why YouTube is the wild card
• The "agentic media platform" pitch 👇
https://t.co/Skx9siRwMx
tweet

God of Prompt
RT @godofprompt: How to use LLMs for competitive intelligence (scraping, analysis, reporting): https://t.co/xlGOSpRQPy
tweet

Brady Long
The era of “prompt and wait for a response” seems to be over.

As soon as I saw this I went immediately to Hugging Face to try it out. Nuts.

https://t.co/JlERquiIcQ

MiniCPM-o 4.5: Seeing, Listening, and Speaking — All at Once. 👁️👂🗣️

✨Beyond traditional turn-taking, we’ve built a Native Full-Duplex engine that allows a 9B model to see, listen, and speak in one concurrent, non-blocking stream.

Watch how it masters real-world complexity in real-time:
🔔 Proactive Auditory Interaction: Interrupts itself to alert you when it hears a "Ding!" while reading cards.
🎨 Temporal Flow Tracking: Follows your pen in real-time, narrating and "mind-reading" your drawing as you sketch.
🍎 Omni-Perception: Scans groceries & identifies prices on the fly.

✨Why it’s a category-leader:
📌Performance: Surpasses GPT-4o and Gemini 2.0 Pro on OpenCompass (Avg. 77.6).
📌Architecture: End-to-end fusion of SigLip2, Whisper, and CosyVoice2 on a Qwen3-8B base.
📌Efficiency: Full-duplex live streaming now runs locally on PCs via llama.cpp-omni.

The era of "Wait-and-Response" AI is over. Proactive, real-time intelligence is now open-source.
🚀Experience it on Hugging Face: 🔗https://t.co/KzzgiGYhVr

#MiniCPM #Omnimodal #FullDuplex #EdgeAI #OpenSource #ComputerVision - OpenBMB
tweet

Moon Dev
I just gave openclaw super powers

it can now use 8 different claude codes to code with Opus all day

So i just turned 1 autonomous ai engineer into 8 https://t.co/IucNIpzVb0
tweet

The Few Bets That Matter
$CROX earnings are pretty interesting.

We’re talking about a company guiding to ~5% EPS growth without growth, only on efficiency, and excluding buybacks after repurchasing ~10% of shares outstanding FY25.

We don’t know how much they’ll buy back in FY26, but you could reasonably model ~10% EPS growth on flat revenue while the stock already trades below peers with weaker financials and fundamentals.

Add to that:
🔹DTC growth - higher margins
🔹International acceleration
🔹HEYDUDE expected to perform better H2-26
🔹Strong brand presence

And you get yourself a real repricing candidate.

If HEYDUDE reaccelerates - and guidance suggests that’s possible with a -8% guidance after a ~-17% Q1, there’s little reason for $CROX to trade at such low multiples versus peers like Nike, which is expected to grow ~4% at best with lower margins.

Plus, risk from here is lower as you'd need worst than terrible to go much lower.

At 10x earnings, you’re looking at roughly a ~$130 stock.
If HEYDUDE improves and multiples expand toward sector norms (~12x), that’s closer to ~$155.

Definitely one to keep an eye on.
tweet

The Transcript
$ABNB CEO: "For the full year 2026, we expect year-over-year revenue growth to accelerate to low double digits with an ambition to grow even faster than that." https://t.co/g7P7M1w8bX
tweet

NecoKronos
Spot is KING 👑

I’ve been saying it for a while: price goes where spot goes. For this entire range, we only saw ask walls forcing the price down.

Yesterday and today, that changed completely. Good support just stacked up on the bid side across spot exchanges.

#BTC https://t.co/Mcn0xwVQzb
tweet

The Few Bets That Matter
$NVO Wegovy pill data continues to look positive.

The thesis that pills would be a major hit given many patients refuse injections seems validated, with ~36% of patients completely new to GLP-1s.

$NVO also plans to raise the price of Wegovy pills from $149 to $199 in April.

That should help growth, although it’s fair to assume this hike was already priced into recent guidance and a study shows that many injectable patients would switch to pills once their reserves empty, which would reduce growth as the injections are slightly more expensive than the pills.

It’s hard to be very optimistic on the stock short term given that guidance. But data remain very strong.

$NVO is back in the $50s.
Look at that. Who could have guessed.

The market always rewards patience; either by giving you liquidity at key levels or by giving you time to change your mind on what could have been a terrible trade.

I took shit for not buying the downtrend.
I took shit when the stock bounced.

And I will still end up with a better average price than the DCA crowd.

Taking shit is often a sign you’re doing something right on social media.
https://t.co/PmRyeSq4cp - The Few Bets That Matter
tweet